Efficacy and clinical safety of vaccination against human papillomavirus
https://doi.org/10.52888/0514-2515-2025-366-3-11-19
Abstract
Objective: to review evidence from high-income countries on HPV vaccination effectiveness and clinical safety to inform the planning of an immunization campaign in the Republic of Tajikistan.
Material and methods. A literature search was conducted to identify clinical and epidemiological studies on the effectiveness and safety of human papillomavirus (HPV) vaccines administered within the past 10–15 years (MEDLINE/ PubMed, WHO sources, and other relevant databases).
Results. HPV vaccines are highly effective (97-100%) at preventing cervical precancer and cancer. Numerous multicenter studies have shown that HPV 16 and HPV 18 infection declined by 90% in age cohorts targeted by routine vaccination. The incidence of anogenital warts among young men and women has decreased by 88%, and the incidence of severe cervical intraepithelial neoplasia (CIN2+) has decreased by 70%. In many countries that introduced the vaccination of adolescent girls, the incidence of invasive cervical cancer has fallen, and in some settings, it has approached near-zero levels among women of reproductive age. In 2017, the WHO Global Advisory Committee on Vaccine Safety issued a statement affirming the safety of HPV vaccines and reaffirming WHO recommendations for their worldwide use.
Conclusion. Inclusion of HPV vaccination in the immunization schedule is an important step towards eliminating cervical cancer in Tajikistan. The quadrivalent vaccine Gardasil, which is intended for the immunization of 10-year-old girls, has demonstrated high effectiveness (over 95–97%) and a well-established clinical safety profile.
About the Authors
J. A. Abdullozoda
Ministry of Health and Social Protection of the Republic of Tajikistan
Tajikistan
Competing Interests:
Tajikistan
Abdullozoda Jamoliddin Abdullo, Doctor of Medical Sciences, Professor, Department of General Surgery No. 2; Minister of Health and Social Protection of the Republic of Tajikistan
Dushanbe
Competing Interests:
Authors declare no conflict of interest
F. B. Saidzoda
SI “Republican Center for Immunoprophylaxis”
Tajikistan
Competing Interests:
Tajikistan
Saidzoda Faizali Barot, Director
Dushanbe
Competing Interests:
Authors declare no conflict of interest
A. I. Murodzoda
SI “Republican Oncology Research Center”
Tajikistan
Competing Interests:
Tajikistan
Murodzoda Akbar Ismatulloevich, Candidate of Medical Sciences, Director
Dushanbe
Competing Interests:
Authors declare no conflict of interest
N. A. Muhsinzoda
SI “Republican Oncology Research Center”
Tajikistan
Competing Interests:
Tajikistan
Muhsinzoda Nilufar Abdukakhhorovna, Candidate of Medical Sciences, Head of the Department of Reproductive System Tumors
Dushanbe
Competing Interests:
Authors declare no conflict of interest
R. A. Tursunzoda
Public Health Association of Tajikistan
Tajikistan
Competing Interests:
Tajikistan
Tursunzoda Rustam Abdusamad, Candidate of Medical Sciences, Director
Dushanbe
Competing Interests:
Authors declare no conflict of interest
References
1. Wu J., Jin Q., Zhang Y., Ji Y., Li J., Liu X., Duan H., Feng Z., Liu Y., Zhang Y., Lyu Z., Yang L., Huang Y. Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022. J Natl Cancer Cent. 2025 Jan 23;5(3):322-329. https://doi.org/10.1016/j.jncc.2024.11.006
2. Ministry of Health and Social Protection of the Population of the Republic of Tajikistan, State Institution “Republican Center for Statistics and Medical Information”. Health of the population and activities of healthcare institutions in 2024. Dushanbe; 2025.
3. Okunade K.S. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020 Jul;40(5):602-608. DOI: 10.1080/01443615.2019.1634030.
4. Derbie A., Mekonnen D., Nibret E., Misgan E., Maier M., Woldeamanuel Y., Abebe T. Cervical cancer in Ethiopia: a review of the literature. Cancer Causes Control. 2023;34(1):1-11. DOI: 10.1007/s10552-022-01638-y.
5. Krasnopolsky V.I., Zarochentseva N.V., Mikaelyan A.V. et al. The role of human papillomavirus infection in pregnancy pathology and neonatal outcome (current concepts). Russian Bulletin of ObstetricianGynecologist. 2016;16(2):30–36.
6. Muhsinzoda N.A., Barotova B.U., Kiyobekova G.A., Tursunov R.A. First experience of human papillomavirus testing in the Republic of Tajikistan. Voprosy Onkologii. 2024;70(3):564–568. DOI: 10.37469/0507-3758-2024-70-3-564-568
7. Muhsinzoda N.A., Muhsinzoda G.M., Saidzoda F.B., Tursunov R.A. Preparing the healthcare system for routine vaccination against human papillomavirus. Sino. 2024;5(1):5–20. DOI: 10.54538/2707-5265-2024-5-1-5-20
8. Cancer: Principles and Practice of Oncology (12th edition). DeVita V.T., Lawrence T.S., Rosenberg S.A. Wolters Kluwer, 2023.
9. Klynishkova T.V. Cervical screening strategy: a modern view. Russian Bulletin of ObstetricianGynecologist. 2023;23(4):20–26. DOI: 10.17116/rosakush20232304120
10. Blake D.R., Middleman A.B. Human papillomavirus vaccine update. Pediatr Clin North Am. 2017; 64: 321- 329. DOI: 10.1016/j.pcl.2016.11.003
11. On carrying out a mass immunization campaign against HPV in the Republic of Tajikistan: Decree of the Government of the Republic of Tajikistan of July 24, 2025 No. 408.
12. Shimabukuro T.T., Su J.R., Marquez P.L., Mba-Jonas A., Arana J.E., Cano M.V. Safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019 Dec;144(6):e20191791. DOI: 10.1542/peds.2019-1791. PMID: 31740500.
13. Mosina L. Presentations and materials presented to the working group during a 10-day seminar to prepare the health sector of Tajikistan for HPV vaccination. Dushanbe, Tajikistan. August 2025.
14. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia grade 3 or worse: analysis of the end-of-study of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012 Jan;13(1):89-99. DOI: 10.1016/S1470-2045(11)70286-8
15. Kjaer S.K., Sigurdsson K., Iversen O.E., HernandezAvila M., Wheeler C.M., Perez G., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009 Oct;2(10):868- 78. DOI: 10.1158/1940-6207.CAPR-09-0031.
16. Joura E.A., Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711-23. DOI: 10.1056/NEJMoa1405044. PMID: 25693011.
17. Wang R., Guo X.L., Wisman G.B.A., Schuuring E., Wang W.F., Feng Z., et al. Nationwide HPV vaccination program in China: economic evaluation, affordability, and cost-effectiveness. Expert Rev Vaccines. 2022 Jul;21(7):1019-1031. DOI: 10.1080/14760584.2022.2071702.
18. World Health Organization (WHO). Global Advisory Committee on Vaccine Safety (GACVS) report, 7-8 June 2017. Human papillomavirus vaccines [Internet]. 2017 [cited 2024 Apr 10]. Available from: https://www.who.int/groups/global-advisory-committee-on-vaccinesafety/topics/human-papillomavirus-vaccines
19. Wang R., Guo X.L., Wisman G.B.A., Schuuring E., Wang W.F., Feng Z., et al. Nationwide HPV vaccination program in China: economic evaluation, affordability, and cost-effectiveness. Expert Rev Vaccines. 2022 Jul;21(7):1019-1031. DOI: 10.1080/14760584.2022.2129615.
20. Falcaro M., Castañon A., Ndlela B., Checchi M., Soldan K., Lopez-Bernal J., et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021 Dec 4;398(10316):2084-2092. DOI: 10.1016/S0140-6736(21)02178-4.
21. Luostarinen T., Apter D., Dillner J., Eriksson T., Harjula K., Natunen K., et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018 Jun 15;142(12):2186-2187. DOI: 10.1002/ijc.31231.
22. Khawar M., Tariq M., Tahir F., Afzal N., Hamid H., Afzal J., et al. Safety of human papillomavirus vaccines: an updated review. Lancet Reg Health West Pac. 2021 Sep 9;16:100258. DOI: 10.1016/j.lanwpc.2021.100258.
23. Niccolai L.M., Hansen C.E. Practice- and communitybased interventions to increase human papillomavirus vaccine coverage: a systematic review. JAMA Pediatr. 2015 Jul;169(7):686-92. DOI:10.1001/jamapediatrics.2015.0310. PMID: 26010507.
24. Donahue J.G., Kike B.A., Lewis E.M., Weintraub E.S., Hanson K.E., McClure D.L., et al. Nearreal-time surveillance to evaluate the safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6):e20191808. DOI: 10.1542/peds.2019-1808
25. Macartney K.K., Chiu C., Georgousakis M., Brotherton J.M. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013 Jun;36(6):393-412. DOI: 10.1007/s40264-013-0039-5. PMID: 23637071.
26. Arbyn M., Xu L., Simoens C., Martin-Hirsch P.P. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. DOI: 10.1002/14651858.CD009069.pub3.
Review
For citations:
Abdullozoda J.A., Saidzoda F.B., Murodzoda A.I., Muhsinzoda N.A., Tursunzoda R.A. Efficacy and clinical safety of vaccination against human papillomavirus. Health care of Tajikistan. 2025;(3):11-19. (In Russ.) https://doi.org/10.52888/0514-2515-2025-366-3-11-19
Views:
32
Email this article 